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Abstract
The role of obestatin, a 23-amino-acid peptide encoded by the ghrelin gene, on the control of the metabolism of pre-adipocyte and
adipocytes as well as on adipogenesis was determined. For in vitro assays, pre-adipocyte and adipocyte 3T3-L1 cells were used to assess
the obestatin effect on cell metabolism and adipogenesis based on the regulation of the key enzymatic nodes, Akt and AMPK and their down-
stream targets. For in vivo assays, white adipose tissue (WAT) was obtained from male rats under continuous subcutaneous infusion of
obestatin. Obestatin activated Akt and its downstream targets, GSK3/, mTOR and S6K1, in 3T3-L1 adipocyte cells. Simultaneously,
obestatin inactivated AMPK in this cell model. In keeping with this, ACC phosphorylation was also decreased. This fact was confirmed 
in vivo in white adipose tissue (omental, subcutaneous and gonadal) obtained from male rats under continuous sc infusion of obestatin 
(24 and 72 hrs). The relevance of obestatin as regulator of adipocyte metabolism was supported by AS160 phosphorylation, GLUT4 translo-
cation and augment of glucose uptake in 3T3-L1 adipocyte cells. In contrast, obestatin failed to modify translocation of fatty acid transporters,
FATP1, FATP4 and FAT/CD36, to plasma membrane. Obestatin treatment in combination with IBMX and DEX showed to regulate the
expression of C/EBP, C/EBP, C/EBP and PPAR promoting adipogenesis. Remarkable, preproghrelin expression, and thus obestatin
expression, increased during adipogenesis being sustained throughout terminal differentiation. Neutralization of endogenous obestatin
secreted by 3T3-L1 cells by anti-obestatin antibody decreased adipocyte differentiation. Furthermore, knockdown experiments by preproghrelin
siRNA supported that obestatin contributes to adipogenesis. In summary, obestatin promotes adipogenesis in an autocrine/paracrine
manner, being a regulator of adipocyte metabolism. These data point to a putative role in the pathogenesis of metabolic syndrome.
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Introduction
The program of adipogenesis is orchestrated by a sequential 
activation of transcription factors transducing information from
intracellular and extracellular factors indicative of suitable condi-
tions for differentiation [1–3]. Several factors have been associated
with dynamic changes of adipose tissue [4]. Particular attention
was recently given to the role of the gastric hormone, ghrelin, on
its role in the regulation of adipocyte biology [5]. The net effect of
prolonged ghrelin exposure is hyperphagia [6, 7]. At central level,
ghrelin promote ubiquitous fat deposition independent of its 
orexigenic activity [6, 8, 9]. Peripheral ghrelin promotes the
enlargement of adipocytes in specific abdominal white adipose 
tissue (WAT) deposits by enhancing lipid accumulation [10]. This
is further supported by augment of adipogenesis [11, 12], 
intracellular lipid accumulation [13], triglyceride content [14] and
reduction of lipolysis [10, 14, 15].
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The ghrelin gene encodes a polypeptide called preproghrelin,
which undergoes stepwise processing to produce ghrelin [16].
Preproghrelin undergoes additional proteolytic cleavage, generat-
ing a 23-amino-acid peptide named obestatin [17]. This peptide
was originally isolated from stomach showing to be a circulating
peptide whose secretion is pulsatile and displays an ultradian
rhythmicity similar to ghrelin and growth hormone secretion [17].
It was originally reported to be the ligand for the orphan receptor
GPR39, which belongs to the family of the ghrelin receptor GHS-
R1a and the motilin receptor [17]. Despite the initial enthusiasm
about the potential of this molecule as a physiological opponent of
ghrelin, several observations related to this point have set its
effectiveness into question [18–21]. Consequently, the state-of-
knowledge on obestatin suffers from serious gaps, especially for
the lack of reproducibility of its central activities. Keeping aside its
controversial anorexigenic activity, there are data suggesting a 
relevant biological role, such as the mitogenic effect described in
3T3-L1 pre-adipocyte [21], human gastric carcinoma [22, 23] and
pancreatic  cells [24]. Furthermore, obestatin induced c-fos
expression in gastrointestinal and white adipose tissues through
binding to GPR39 [21]. Of interest, GPR39 expression in white
adipose tissues of rats was up-regulated during fasting whereas
GPR39 levels were decreased in cultured mouse embryonic
fibroblast cell lines during adipogenesis [25]. In human adipose
tissue, decreased GPR39 expression was found in patients with
obesity-associated type 2 diabetes mellitus [26]. These findings
suggest a possible role for obestatin in adipocyte function. Thus,
to shed light on the hypothetical role of obestatin in the biology
and pathology of adipose tissue, we determined the effect of
obestatin on the control of the metabolism of adipocyte and WAT
as well as on adipogenesis focusing on the regulation of key enzy-
matic nodes for metabolism, Akt and AMPK [27, 28].
Methods
Materials
Rat/mouse obestatin was obtained from California Peptide Research (CA,
USA). Mouse ghrelin was obtained from Global Peptides (CO, USA). Insulin
was obtained from NovoNordisk (Bagsvaerd, Denmark). Anti-pAkt HM
(S473), anti-pAMPK(T172), anti-pGSK3/(S21/9), anti-pmTOR(S2448),
anti-pS6K1(T389), anti-pACC(S79), anti-GLUT4 and anti-tubulin antibodies
were from Cell Signaling Technology (MA, USA). Anti-pAS160(T642) 
antibody was obtained from Millipore (CA, USA). Preproghrelin siRNA,
control siRNA, anti-GLUT1, anti-FAT/CD36, anti-FATP1, anti-FATP4, 
anti-C/EBP, anti-C/EBP, anti-C/EBP, anti-PPAR and anti-GHSR1a
antibodies were obtained from Santa Cruz Biotechnology (CA, USA).
GPR39 siRNAs were obtained from Applied Biosystems/Ambion (TX,
USA). Anti-GPR39 antibody was obtained from Abcam (Cambridge, UK).
For IHC, anti-obestatin antibody was from Alpha Diagnostic International
(TX, USA). Anti-obestatin (obestatin neutralization assays) and anti-
preproghrelin antibodies were obtained from Phoenix Pharmaceuticals
(CA, USA). Secondary antibodies, enhanced chemiluminescence 
detection system and 2-[3H]deoxyglucose were from GE-Amersham
(Buckinghamshire, UK). Alzet® osmotic minipumps (model 1003D) were
purchased from Alzet Corporation (CA, USA). All other chemical reagents
were from Sigma (MO, USA).
Animals
Adult male Sprague–Dawley rats (250 g; n  40) were housed in 12-hr
light/12-hr dark cycles with free access to standard rat chow diet and
water. Alzet® minipumps (model 1003D) were sc implanted. The animals
were assigned to one of four-matched experimental groups (n 
10/group): 1) 24 hr-minipump sc implanted group [containing obestatin
(300 nmol/kg body weight/24 h)]; 2) 24 hr-minipumps sc control group
(containing saline); 3) 72 hr-minipump sc implanted group [containing
obestatin (300 nmol/kg body weight/24 hrs)] and 4) 72 hr-minipumps sc
control group (containing saline). These minipumps hold 100 l volume
and deliver 1 l/h. After 24 or 72 hrs, rats were euthanatized to obtain
omental, subcutaneous and gonadal adipose tissues.
Cell culture and differentiation induction of 3T3-L1
pre-adipocytes
3T3-L1 pre-adipocytes were maintained in DMEM containing 10% foetal
bovine serum (FBS), 100 U/ml penicillin and 100 U/ml streptomycin. For
routine differentiation, confluent cells were treated with 0.5 mM isobutyl-
methylxantine (IBMX), 25 M dexamethasone (DEX) and 861 nM 
(5 g/ml) insulin for 3 days and maintained in DMEM containing 10% FBS,
100 U/ml penicillin, 100 U/ml streptomycin and supplemented with 
172 nM (1 g/ml) insulin for 10 days after the beginning of differentiation
unless otherwise stated. Before each experiment 3T3-L1 pre-adipocytes or
adipocyte cells were serum-starved 12 hrs in DMEM.
Western blot analysis
Tissue samples or serum-starved cells were stimulated with obestatin for
the indicated time period at 37°C. The media was then aspirated and the
cells were directly lysed in ice-cold RIPA buffer [Tris-HCl (pH 7.2), 50 mM;
NaCl, 150 mM; EDTA, 1 mM; NP-40, 1% (v/v); Na-deoxycholate, 0.25%
(w/v); protease inhibitor cocktail (Sigma); phosphatase inhibitor cocktail
(Sigma)]. Lysates were clarified by centrifugation (14,000  g for 15 min.
at 4	C) and the protein concentration was quantified performed with the
QuantiProTM BCA assay kit (Sigma). For immunoblotting, equal amounts of
protein were fractionated by SDS-PAGE and transferred onto nitrocellulose
membranes. Immunoreactive bands were detected by enhanced chemilu-
minescence (ECL Plus Western blotting kit; GE-Amersham).
Western blot analysis of GLUT1, GLUT4, FAT/CD36,
FATP1 and FATP4 in plasma membrane
Serum-starved cells were treated with obestatin (100 nM) or insulin (172 nM)
for 60 min. and then harvested by scraping. After centrifugation, pellets
were resuspended in homogenization buffer [HEPES (pH 7.4), 20 mM;
sucrose, 255 mM; EDTA, 2 mM; protease inhibitor cocktail (Sigma); 
phosphatase inhibitor cocktail (Sigma)], homogenized with eight strokes,
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and then centrifuged at 1200  g for 5 min. at 4°C to remove nuclei and
unbroken cells. The supernatant was then centrifuged at 195,000  g for
60 min. at 4°C to obtain total membranes. The final pellet was resuspended
in homogenization buffer and used for western blot analysis.
Real time quantitative reverse transcription PCR
(qRT-PCR)
For qRT-PCR, total RNA was isolated with Trizol (Invitrogen, CA, USA) and
DNA-free kit (Applied Biosystems/Ambion, TX, USA) to generate first-
strand cDNA synthesis performed with High-capacity cDNA Reverse
Transcription kit (Applied Biosystems). qRT-PCR was performed using an
ABI PRISM 7300 HT Sequence Detection System (Applied Biosystems).
For the analysis of the preproghrelin gene, ACTB was used as housekeeping
gene (TaqMan: Applied Biosystems). The fold change in gene expression
was calculated using the 2
Ct relative quantitation method according to
the manufacturer’s guidelines (Applied Biosystems).
Quantification and staining of lipids with Oil Red O
Treated cells were fixed for 1 hr with 4% buffered paraformaldehyde-PBS.
Each dish was rinsed three times with Milli-Q water and then with 60% 
iso-propanol (5 min. at room temperature). Lipid droplets were stained for
10 min. at room temperature with a working solution of 60% Oil Red O. For
quantification, cells were washed extensively with water to remove
unbound dye, and iso-propanol was added to the stained culture plates and
then analysed by spectrophotometry at 520 nm.
Immunohistochemistry
Cells were fixed on cover slips in 96% ethanol. White adipose tissue 
samples were fixed by immersion in 10% buffered formalin for 24 hrs,
dehydrated and embedded in paraffin by a standard procedure. Sections, 
5 m thick, were mounted on Histobond Adhesion Microslides
(Marienfeld, Lauda-Königshofen, Germany), dewaxed and rehydrated.
Slides were consecutively incubated with: 1) anti-obestatin rabbit 
polyclonal antibody at a dilution of 1:100 in Dako ChemMate antibody 
diluent (Dako, Glostrup, Denmark); 2) EnVision peroxidase rabbit (Dako,
CA, USA) used as the detection system and 3) 3,3-diaminobenzidine-
tetrahydrochloride (Dako Liquid DAB  Substrate-chromogen system).
Cell and tissue sections were faintly counterstained with Harris’ 
haematoxylin. Immunohistochemistry controls were performed applying
the primary antibody plus control antigen peptide (10 nmol/ml) to 
positive samples.
Small interfering RNA (siRNA) silencing of gene
expression
Chemically synthesized double-stranded siRNA duplexes (Santa Cruz
Biothecnology) were for preproghrelin: 3-CAGAGAAAGGAAUCCAAGA-5,
3-CCUUCGAUGUUGGCAUCAA-5 and 3-CUCUCCUACCACUUUAAGA-5.
GPR39 targeted siRNAs (Ambion siRNA sequence numbers s89441,
s89442, s89443) were selected from Silencer® Pre-designed sequences
from Applied Biosystems. A non-silencing RNA duplex was used as a con-
trol for all siRNA experiments. 3T3-L1 cells were transfected with
Lipofectamine 2000 (Invitrogen).
Immunofluorescence analysis of GLUT translocation
3T3-L1 cells were cultured on cover slips and differentiated into
adipocytes. Serum-starved cells were treated with obestatin (100 nM) or
insulin (172 nM) for 30 min. Intact cells were fixed with 4% buffered
paraformaldehyde-PBS for 15 min., washed, permeabilized and blocked
with PBT [1% Triton X-100, 1% Tween-20, 5% heat inactivated normal
goat serum, 0.2% BSA in PBS] for 30 min., and then incubated with anti-
Glut4 rabbit antibody diluted in PBT (1:100) overnight at 4°C. After three
washes with PBS, cells were incubated with the secondary antibody (Alexa
594-conjugate goat anti-rabbit antibody) in PBT (1:500) for 45 min. at
37°C. Fluorescent images were captured with a Leica TCS SP 2
(LeicaMicrosystems, Heidelberg, Germany) confocal laser scanning micro-
scope mounted on an Leica DM IRBE inverted microscope.
2-[3H]Deoxyglucose uptake (DOGU)
3T3-L1 adipocytes cells were cultured in six-well culture plates. Serum-
starved cells (12 hrs) were washed with PBS buffer and incubated for 
10 min. in PBS supplemented with 0.1% BSA. Then cells were either
unstimulated or stimulated with obestatinghrelin or insulin at the indicated
concentrations for 30 min. Glucose transport was determined by addition
of 2-[3H]deoxyglucose (0.5 Ci/ml). The uptake was stopped after 5 min.
by aspiration, and cells were washed three times with ice-cold PBS. Cells
were lysed in 1% SDS, and deoxyglucose uptake was determined by scin-
tillation counting in triplicate. Non-specific uptake was measured in the
presence of 20 M cytochalasin B (cyB).
Data analysis
Comparisons between groups were made by ANOVA. P  0.05 was con-
sidered as statistically significant (*,#,##).
Results
Obestatin activates Akt phosphorylation and AMPK
dephosphorylation in 3T3-L1 adipocyte cells
First, the dose dependence of Akt activation by obestatin was
examined in 3T3-L1 adipocytes. Akt phosphorylation at C-terminal
hydrophobic motif (S473) [HM(S473); pAkt(S473)] was observed
using 10 nM obestatin, and the level of pAkt(S473) plateaued at
100–200 nM (data not shown). Next, we examined the kinetic of
Akt activation in response to obestatin. Significant pAkt(S473)
augment was observed 10 min. after addition of obestatin 
(100 nM), being sustained by 60 min. (Fig. 1A). Parallel to Akt
activation, obestatin (100 nM) triggered the phosphorylation of a
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broad range of Akt downstream substrates: GSK3/ (S21/9),
AS160(T642), mTOR(S2448) and S6K1(T384) (Fig. 1B and C).
Importantly, dephosphorylation of pAMPK(T172) and its down-
stream substrate ACC(S79) was observed in response to obestatin
(100 nM) (Fig. 1C).
Obestatin activates Akt phosphorylation and AMPK
dephosphorylation in WAT
For in vivo obestatin administration, osmotic minipumps were
selected based on the short half-life of this peptide (~22 min.)
Fig. 1 Obestatin activates Akt phosphorylation and AMPK dephosphorylation in 3T3-L1 adipocyte cells and WAT. Time-course of the effect of obestatin
(100 nM) on: (A) pAkt(S473) and pAMPK(T172); (B) pGSK3/(S21/9) and pAS160(T642) and (C) pmTOR(S2448), pS6K1(T384) and pACC(S79).
Phosphorylation was expressed as a percentage of the maximal phosphorylation obtained for each residue (n  3; meanS.E.). Blots are representative
of three independent experiments. (D) Effect of 24 hrs continuous sc infusion of obestatin (300 nmol/kg body weight/24 hrs; n  10) on pAkt(S473) 
and pAMPK(T172) from subcutaneous, gonadal and omental WAT obtained from male rats. (E) Effect of 72 hrs continuous sc infusion of obestatin 
(300 nmol/kg body weight/24 hrs; n  10) on pAkt(S473) and pAMPK(T172) from subcutaneous, gonadal and omental WAT obtained from male rats.
Phosphorylation was expressed as a percentage of control obtained from 24 hrs or 72 hrs-minipump sc implanted saline group (n  10; meanS.E.).
Asterisk (*) denotes P  0.05 when comparing obestatin-treated group with untreated control group (saline).
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[29]. Male rats received a 24 hrs continuous sc infusion of
obestatin (300 nmol/kg body weight/24 hrs) and dissected WATs
were processed for Western blot analysis. Obestatin significantly
activated Akt, measured as pAkt(S473), in subcutaneous, gonadal
and omental WAT (Fig. 1D). pAMPK(T172) was decreased by
20% to basal phosphorylation in omental WAT with no effect in
subcutaneous and gonadal WAT (Fig. 1D). A 72 hrs continuous sc
infusion of obestatin (300 nmol/kg body weight/24 hrs) increased
pAkt(S473) and decreased pAMPK(T172) in subcutaneous,
gonadal and omental WAT (Fig. 1E). The divergence between 24
and 72 hrs might be explained by the stress generated by mini-
pump implantation. Total Akt and AMPK levels were comparable in
all instances (data not shown).
Obestatin increases GLUT4 levels in plasma
membranes and glucose uptake in 3T3-L1
adipocyte cells
The amplitude of Akt activation was evaluated on the basis to the
GLUT1 and GLUT4 translocation to plasma membrane in 3T3-L1
adipocyte cells. Acute treatment with obestatin (100 nM, 30 min.)
resulted in an increase in GLUT4 translocation to the plasma
membrane by ~1.9-fold (Fig. 2A). Intriguingly, a modest GLUT1
redistribution was observed in response to 100 nM obestatin 
(30 min.) in 3T3-L1 adipocyte cells (~1.3-fold; Fig. 2A). Insulin
(172 nM, 30 min.) caused a higher increase of GLUT4 levels at the
plasma membrane than obestatin in 3T3-L1 adipocyte cells 
(~2.8-fold) with no significant effect on GLUT1 translocation 
(Fig. 2A). The effect of obestatin in the translocation of GLUT4 to
the plasma membrane was confirmed by specific immunofluores-
cence staining (Fig. 2B). In quiescent 3T3-L1 adipocyte cells, the
fluorescence was distributed throughout the cytoplasm. After
exposure to obestatin (100 nM, 30 min.), the fluorescence almost
completely disappeared from the cytoplasm to be redistributed in
the plasma membrane.
The effect of obestatin on DOGU was examined in 3T3-L1
adipocyte cells. Cells were incubated with different concentrations
of obestatin (0.001–200 nM) for 30 min., resulting in a dose-
dependent increase in DOGU with a maximal effect at 100 nM
obestatin (~2.0-fold; Fig. 2C). Insulin treatment (172 nM) caused
an increase of DOGU by ~2.8-fold in adipocyte cells (Fig. 2C).
Obestatin shows no effect on FATP1, FATP4 
and FAT/CD36 translocation to plasma membrane
in 3T3-L1 adipocyte cells
The levels of fatty acid (long chain) transport proteins 1 and 4
(FATP1 and FATP4) and fatty acid translocase (FAT/CD36) at the
plasma membrane were examined by subcellular fractionation. As
shown in Fig. 2D, obestatin (100 nM, 30 min.) did not modify
FATP1, FATP4 and FAT/CD36 levels at the plasma membrane in
3T3-L1 adipocyte cells. Remarkably, FATP1 and FATP4 redistribution
was significantly affected in response to insulin (172 nM, 30 min.)
in ~2.3- and 2.6-fold, respectively. In contrast to the FATP obser-
vation, FAT/CD36 redistribution was unaffected in response to
insulin (172 nM, 30 min.; Fig. 2D).
Obestatin promotes adipogenesis in vitro
To initiate the 3T3-L1 adipocyte differentiation process, IBMX, DEX
and insulin are used. Among these three compounds, only insulin is
capable of activating Akt system through IGF-1 receptor playing a
pivotal role in adipogensis [30]. To ascertain the effect of obestatin
on adipogenesis, we first analysed the effect of obestatin on Akt 
activation in 3T3-L1 pre-adipocytes. Consistent with the effect on
3T3-L1 adipocytes, obestatin (100 nM) induced significant
Akt(S473) phosphorylation, which was parallel to AMPK dephospho-
rylation at T172 in 3T3-L1 pre-adipocyte cells (Fig. 3A). The effect 
of acute GPR39 deficiency was determined by means of siRNA in
3T3-L1 pre-adipocyte cells. Under these conditions, the constructs
decreased GPR39 expression by 5010% (Fig. 3B). In the presence
of a non-targeting control siRNA, obestatin-activated Akt(S473)
phosphorylation was identical to that observed without any transfec-
tion (data not shown). Silencing of GPR39 in pre-adipocyte cells
decreased subsequent pAkt(S473) with respect to siRNA control
(472% under treatment with obestatin (100 nM) for 5 min.;
Fig. 3B). Next, we examined the role of obestatin as promoter of ter-
minal adipocyte differentiation working with 3T3-L1 pre-adipocyte
cells maintained in DMEM containing 10% FBS with obestatin
(0.001–200 nM), ghrelin (0.001–200 nM) or insulin (172 nM) for 
7 days after induction of differentiation under combination of 0.5 mM
IBMX, 25 M DEX and 861 nM insulin for 3 days. Oil red O staining
revealed that the accumulation of lipid droplets was dose-dependent
for obestatin or ghrelin treatments being maximal at 10 nM for both
peptides (~3.6-fold; Fig. 3C). Insulin (172 nM) treatment increased
the formation of lipid droplets (~7.8-fold; Fig. 3C). Cotreatment with
obestatin or ghrelin (1 or 10 nM) and a half-dose of insulin (86 nM)
further stimulated adipocyte differentiation compared to the treat-
ments with obestatin or ghrelin alone (Fig. 3C).
The capability of obestatin as initiator of adipocyte differentiation
was explored by the combination of IBMX, DEX and obestatin
(1.96 M obestatin for 3 days and then maintained in DMEM contain-
ing 10% FBS with 392 nM obestatin for 7 days; Fig. 3D). Obestatin-
stimulated adipocyte differentiation was detected at 10 nM, but
maximal effects were observed at pharmacological levels for in vitro
assays (1 M). Obestatin treatment (1.96 M) for 3 days
(Group 2, Fig. 3D) induced more lipid droplets (~1.6-fold) than insulin
treatment (Group 1, Fig. 3D). The accumulation was higher in cells
maintained in DMEM/10% FBS with obestatin (392 nM) for 7 days
after induction of differentiation (Group 3, Fig. 3D), but fewer than
that observed in full dose insulin-treated cells (172 nM) for 7 days
(Group 4, Fig. 3D). Supporting this scenario, in obestatin-treated
3T3-L1 differentiating adipocytes, C/EBP protein expression
markedly increased at 24 hrs for p32 and p35 isoforms, respectively
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Fig. 2 (A) Western blot analysis of GLUT4 and GLUT1 expression in membrane from 3T3-L1 adipocyte cells treated with obestatin (100 nM) or insulin
(172 nM) for 30 min. GLUT expression was expressed as a percentage of basal expression obtained in control cells (n  3; meanS.E.). (B)
Immunofluorescence analysis of obestatin-induced GLUT4 translocation in 3T3-L1 adipocyte cells. Serum-starved cells were stimulated with obestatin
(100 nM, 30 min.) and the amount of GLUT4 was determined by labelling with anti-GLUT4 antibody in combination with Alexa 594-conjugate goat anti-
rabbit antibody in permeabilized cells. (C) Obestatin dose dependently stimulated 2-[3H]deoxyglucose uptake in 3T3-L1 adipocyte cells (n  3;
meanS.E.). Non-specific uptake was measured in the presence of 20 M cytochalasin B (cyB). (D) Western blot analysis of FATP1, FATP4 and FAT/CD36
expression in membrane from 3T3-L1 adipocyte cells treated with 100 nM obestatin or with 172 nM insulin for 30 min. FATP1, FATP4 and FAT/CD36
expression were expressed as a percentage of basal expression obtained in control cells (n 3; meanS.E.). For (A, D) expression of GHSR1a was deter-
mined to ensure equal membrane protein loading. Blots are representative of three independent experiments. Asterisk (*) denotes P  0.05 when com-
paring obestatin-treated group with untreated control group.
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Fig. 3 (A) Time-course of the effect of obestatin (100 nM) on pAkt(S473) and pAMPK(T172) in 3T3-L1 pre-adipocyte cells. Phosphorylation was expressed
as a percentage of the maximal phosphorylation obtained for each residue (n 3; meanS.E.). (B) Effect of siRNA depletion of GPR39 on obestatin-activated
pAkt(S473) (100 nM, 5 min.) in 3T3-L1 pre-adipocyte cells. Expression of pAkt(S473) and GPR39 was expressed as fold of their levels in control siRNA-trans-
fected cells (n  3; meanS.E.). (C) 3T3-L1 cells display an obestatin-dependent increase in adipogenesis. 3T3-L1 pre-adipocyte cells were maintained in
DMEM containing 10% FBS with different concentrations of obestatin, ghrelin or insulin (172 nM) for 7 days after induction of differentiation by combination
of 0.5 mM IBMX/25 M DEX/861 nM insulin for 3 days. Lipid droplet accumulation was analysed by spectrophotometry at 520 nm by Oil red O staining. Results
are expressed as a fold of lipid accumulation over differentiation control (cells maintained in DMEM/10% FBS/172 nM insulin for 7 days after induction of dif-
ferentiation under treatment with 0.5 mM IBMX/25 M DEX/861 nM insulin for 3 days; n  3; meanS.E.). Representative microscope fields of view (right)
are shown at the same magnification. (D) Effect of obestatin as initiatr of adipogenesis. 3T3-L1 pre-adipocyte cells were maintained in DMEM containing 10%
FBS with obestatin (392 nM) or insulin (172 nM) for 7 days after induction of differentiation by treatment with 0.5 mM IBMX, 25 M DEX, 861 nM insulin or
1.96 M obestatin for 3 days. Lipid droplet accumulation was analysed by spectrophotometry at 520 nm by Oil red O staining. Results are expressed as fold
of lipid accumulation over differentiation control (cells maintained in DMEM/10% FBS/172 nM insulin for 7 days after induction of differentiation by treatment
with 0.5 mM IBMX/25 M DEX/861 nM insulin for 3 days; n  3; meanS.E.). Asterisk (*) denotes P  0.05.
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(Fig. 4A). Furthermore, C/EBP protein expression peaked around 
6 hrs after obestatin treatment (Fig. 4B). Consistently, obestatin
treatment strongly increased the expression of PPAR proteins
peaking at 48 and 144 hrs of differentiation for PPAR1 and
PPAR2 isoforms, respectively (Fig. 4C). In addition, this treat-
ment also increased the expression of C/EBP proteins peaking at
24 and 72 hrs for p30 and p42 isoforms, respectively (Fig. 4D).
Preproghrelin expression increases throughout
adipogenesis
We first examine obestatin expression in 3T3-L1 pre-adipocyte
and adipocyte cells at protein level, utilizing immunocytochemistry.
3T3-L1 adipocyte cells showed a stronger obestatin expression
(Fig. 5B) compared to that observed in 3T3-L1 pre-adipocyte cells
(Fig. 5A). No immunostaining was found with obestatin antibody
pre-adsorption control in 3T3-L1 adipocyte cells (Fig. 5C). This
result leads us to focus on preproghrelin expression along adipo-
genesis as source of obestatin. Preproghrelin expression was
examined at mRNA and protein level, by RT-PCR and immunoblot,
respectively, in 3T3-L1 pre-adipocyte cells. The cells were main-
tained in DMEM containing 10% FBS with insulin (172 nM) for 
7 days after induction for 3 days (0.5 mM IBMX, 25 M DEX and
861 nM insulin). The amount of preproghrelin mRNA showed a
biphasic pattern of expression. A rapid augment was observed at
6 hrs (~1.7-fold; Fig. 5D), to reach values bellow basal by 24 hrs
after the induction of differentiation. Preproghrelin mRNA expres-
sion increased from 48 hrs, becoming maximal 72 hrs after induc-
tion to be sustained throughout terminal differentiation. As Fig. 5E
shows, there is a rapid augment of preproghrelin protein expres-
sion at the time of differentiation into adipocytes (~4.0-fold, 6 hrs
after induction) reaching a maximum 24 hrs after induction of 
differentiation (~5.8-fold) concomitant with the minimum of pre-
proghrelin mRNA expression (Fig. 5D). Intriguingly, preproghrelin
protein expression decreased 48 hrs after induction of differentiation
to be sustained along terminal differentiation being higher than
that in pre-adipocyte cells (~2.4-fold at 240 hrs). Furthermore,
GPR39 protein expression decreased in terminal differentiation
compared to undifferentiated 3T3-L1 cells (~40% reduction, 
© 2011 The Authors
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Fig. 4 Immunoblots showing the expression pattern of: (A) C/EBP, (B) C/EBP , (C) PPAR and (D) C/EBP. 3T3-L1 pre-adipocyte cells were main-
tained in DMEM containing 10% FBS, obestatin (392 nM) or insulin (172 nM) for 7 days after induction of differentiation by treatment with 0.5 mM IBMX,
25 M DEX, 10% FBS, 861 nM insulin or 1.96 M obestatin for 3 days [in (D), asterisk (*) denotes unspecific band]. Data were expressed as percentage
of control expression (n  3; meanS.E.). Blots are representative of three independent experiments.
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240 hrs after induction; Fig. 5F), showing two maximal expression
levels concomitant with the maximum of preproghrelin expression
(Fig. 5D). Consistent with the results from cultured cells, immuno-
histochemical analysis confirmed the expression of obestatin in
subcutaneous, gonadal and omental WAT obtained from male ad
libitum rats (Fig 5G–I, respectively).
Autocrine/paracrine role of obestatin 
on adipogenesis
The autocrine/paracrine role of obestatin on adipogenesis was
tested in vitro performed with a neutralizing obestatin antibody
(anti-obestatin Ab). As shown in the Fig. 6A (left panel) neutralization
© 2011 The Authors
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Fig. 5 Immunocytochemical detection of obestatin in 3T3-L1 pre-adipocyte (A) and adipocyte cells (B) (objective magnification 40). Obestatin
immunostaining was mainly localized in the cytoplasm of 3T3-L1 adipocytes while it was faint in 3T3-L1pre-adipocyte cells. (C) Pre-adsorption control
with mouse obestatin (10 nmol/ml) showed no positive immunostaining. (D) Preproghrelin mRNA levels in the course of adipogenesis. (E, F) Western
blot analysis of preproghrelin (E) and GPR39 (F) expression in the course of adipogenesis. Preproghrelin expression at mRNA or protein levels, were
examined in 3T3-L1 pre-adipocyte cells maintained in DMEM containing 10% FBS with insulin (172 nM) for 7 days after induction for 3 days (0.5 mM
IBMX, 25 M DEX and 861 nM insulin). Protein expression was expressed as a fold over control cells (n  3; meanS.E.). mRNA was quantified by RT-PCR
and expressed as arbitrary units (n  5; meanS.E.). (G–I) Immunohistochemical detection of obestatin in subcutaneous (G), gonadal (H) and omental
(I) WAT (objective magnification 20). Asterisk (*) denotes P  0.05 when comparing obestatin-treated group with untreated control group.
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of obestatin (100 nM) by preincubation with anti-obestatin Ab (1.3
g/ml) reduced by ~703% the level of pAkt(S473) in 
3T3-L1 pre-adipocyte cells. By contrast, insulin-induced Akt activity
was not affected by preincubation with anti-obestatin Ab. The
autocrine/paracrine role on adipogenesis was then tested by com-
bination of serum-free conditioned medium by 3T3-L1 adipocyte
cells (CM, 24 and 48 hrs) with neutralizing obestatin antibody 
(5 g/ml). 3T3-L1 pre-adipocyte cells were maintained in DMEM
containing 0.1% BSA with obestatin (392 nM; Group 2), anti-
obestatin Ab, (Group 3), obestatin (392 nM)anti-obestatin Ab
(Group 4), CM-24h (Group 5), CM-24hanti-obestatin Ab (Group 6),
CM-48h (Group 7) or CM-48hanti-obestatin Ab (Group 8) for 
7 days after induction of differentiation under treatment with 
0.5 mM IBMX, 25 M DEX and 861 nM insulin for 3 days. Oil Red
O staining revealed that incubation with neutralizing obestatin Ab
reduced by 353% accumulation of lipid droplets compared to
3T3-L1 pre-adipocyte cells maintained in DMEM/0.1% BSA/392 nM
obestatin (Fig. 6A, Group 3 versus Group 2). Neutralization of
obestatin (392 nM) by preincubation with anti-obestatin Ab
reduced by 358% accumulation of lipid droplets compared to
3T3-L1 pre-adipocyte cells maintained in DMEM/0.1% BSA/392 nM
obestatin (Group 4 versus Group 2; Fig. 6A). Serum-free condi-
tioned medium, CM-24h or CM-48h, also activated accumulation
of lipid droplets (~2.0- and ~2.5-fold, respectively; Groups 5 and
7 versus Group 1; Fig. 6A). Preincubation of the CM-24h or 
CM-48h with anti-obestatin Ab reduced accumulation of lipid
droplets by 214% and 206%, respectively (Groups 6 versus
Groups 5, and Group 8 versus Group 7, Fig. 6A). The effect of
acute obestatin deficiency was determined by knockdown of 
preproghrelin by means of siRNA prior to induction of adipocyte
differentiation. Under these conditions, the constructs decreased
preproghrelin expression by 586% (Fig. 6B). In the presence of
a non-targeting control siRNA, obestatin-activated adipocyte dif-
ferentiation was identical to that observed without any transfection
(data not shown). Silencing of preproghrelin in pre-adipocyte cells
decreased subsequent adipocyte differentiation with respect to
siRNA control [435% and 484% for 3T3-L1 pre-adipocyte
cells under treatment with 0.5 mM IBMX, 25 M DEX, and insulin
(861 nM) for 3 days and then maintained in DMEM containing
10% FBS or insulin (172 nM) for 7 days, respectively (Fig. 6B)].
Discussion
In this study, we provide the first evidence that obestatin regulates
adipocyte metabolism and adipogenesis. Preproghrelin expression,
and thus obestatin, increased during adipogenesis being sustained
throughout terminal differentiation of 3T3-L1 cells. In vitro 3T3-L1
cells secreted obestatin whose effects on adipocyte differentiation
were neutralized by an obestatin antibody. Preproghrelin knock-
down experiments revealed that obestatin contributes to adipogen-
esis, a fact that is supported by the effect of exogenous obestatin on
the expression of C/EBP, C/EBP, C/EBP and PPAR and, conse-
quently, lipid accumulation. In 3T3-L1 adipocyte cells, obestatin
activated Akt phosphorylation and its downstream targets,
GSK3/, mTOR, S6K1 and inhibited AMPK activity. This fact was
confirmed in vivo in omental, subcutaneous and gonadal WAT
obtained from male rats under continuous sc infusion of obestatin.
The relevance of obestatin as regulator of pre-adipocyte/ adipocyte
metabolism was also supported by AS160 phosphorylation, GLUT4
translocation and augment of glucose uptake in 3T3-L1 adipocyte
cells. By contrast, obestatin failed to modify translocation of fatty
acid transporters, FATP4 and FAT/CD36, to plasma membrane.
Exposure of 3T3-L1 cells, a well-characterized model for
studying the differentiation of white adipocytes, to obestatin regu-
lated Akt activity. This study also demonstrated that chronic 
in vivo obestatin administration in male rats enhanced Akt activity
in omental, subcutaneous and gonadal fat. It is well known that
Akt regulates mammalian cell cycle progression and cell survival
[27]. Furthermore, there is strong evidence, including results
obtained from genetic mouse models, supporting the concept that
Akt is a key node for regulation of a multitude of metabolic events
such as glucose uptake, glycogen synthesis, glyconeogenesis,
lipid metabolism, protein synthesis and differentiation processes
as adipogenesis [27, 30–34]. One of the physiological functions of
Akt is to stimulate glucose uptake by GLUT4 trafficking through
the Rab GAP (GTPase-acting protein) known as AS160 [35–38]. It
was described five putative Akt phosphorylating sites on AS160 of
which T642 appears to be critical for mediating the GLUT4 translo-
cation and glucose uptake in response to insulin [36]. Our results
showed that obestatin increased AS160 phosphorylation on T642,
consistent with Akt mediating obestatin-induced phosphorylation.
AS160 keeps a GAP domain that maintains its target Rab(s) in
their inactive GDP-state. AS160 phosphorylation suppresses its
GAP activity, shifting the equilibrium of its targets Rab(s) to an
active GTP form, enabling it to mediate GLUT4 trafficking [39].
Indeed, obestatin increased GLUT4 membrane translocation and
glucose transport in 3T3-L1 adipocyte cells, although in smaller
extension to that of insulin. Inside the cell, glucose is converted to
glucose 6-phosphate that can be stored by conversion to glycogen
or catabolized by glycolysis, both processes under the control of
Akt signalling [27]. In this sense, obestatin inactivated GSK3/,
an Akt substrate, through phosphorylation in 3T3-L1 adipocyte
cells. This inactivation leads to a decrease in the phosphorylation
of glycogen synthase (GS) resulting in its activation, thereby 
stimulating glycogen synthesis [40]. Apart from GS, translation
initiation factor 2B (eIF2B) can be also activated in a similar way
leading to an increase in the glycogen synthesis and the protein
synthesis [40]. Furthermore, inactivation of GSK3 has been shown
to avoid degradation of the sterol regulatory element-binding 
proteins (SREBPs), which are transcription factors that trigger the
expression of genes involved in cholesterol and fatty acid biosyn-
thesis [41]. Consequently, Akt-directed signaling coordinates the
obestatin-evoked glucose uptake and storage as glycogen in 
adipose tissue by regulation of AS160 and GSK3. In addition to 
glucose uptake, obestatin showed to regulate mTORC1/S6K1 sig-
naling, a critical element integrating cellular metabolism with
growth factor signaling [42]. mTORC1 controls many aspects of
cellular metabolism including fat metabolism [42–44]. In particular,
© 2011 The Authors
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mTORC1/S6K1 plays an important role in adipogenesis and, thus, in
lipid accumulation [43]. Loss of mTORC1/S6K1 activity correlates
with a decrease in fat accumulation, suggesting that the mTOR
pathway is required for fat accumulation [45, 46]. Furthermore, 
activation of mTORC1 signaling is a critical step in adipocyte differ-
entiation [46]. The capacity of obestatin to modulate Akt activity in
pre-adipocyte and adipocyte cells is not an isolated fact since this
kinase is also activated by this peptide in pancreatic®-cell lines,
human islets [24] and gastric cell lines [23]. In gastric cell lines, a
signaling pathway involving a -arrestin 1 scaffolding complex and
EGFR to activate Akt signaling is proposed [23]. It will clearly be of
interest to establish whether this also occurs in adipose cells.
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6 (A) Autocrine/paracrine role of obestatin on adipogenesis. (Right panel) 3T3-L1 pre-adipocyte cells were maintained in DMEM containing 0.1%
BSA with obestatin (392 nM; Group 2), anti-obestatin antibody (5 g/ml; anti-obestatin Ab; Group 3), obestatin (392 nM)anti-obestatin Ab (5 g/ml;
Group 4), CM-24h (Group 5), CM-24hanti-obestatin Ab (5 g/ml; Group 6), CM-48h (Group 7) or CM-48hanti-obestatin Ab (5 g/ml; Group 8) for
7 days after induction of differentiation by treatment with 0.5 mM IBMX, 25 M DEX and 861 nM insulin for 3 days. Lipid droplet accumulation was
analysed by spectrophotometry (520 nm) by Oil red O staining. Results are expressed as fold of lipid accumulation over differentiation control (Group 1;
cells maintained in DMEM/0.1% BSA for 7 days after induction of differentiation by treatment with 0.5 mM IBMX/25 M DEX/861 nM insulin for 3 days;
meanS.E. of three independent experiments). Asterisk (*) denotes P  0.05 when comparing treated Groups with control Group (Group1); daggers 
(#, ##) denote P  0.05 when comparing treated Groups with antibody-treated Groups. (Left panel) Anti-obestatin antibody specificity. Effect of anti-
obestatin antibody (1.3 g/ml), obestatin (100 nM), insulin (100 nM), anti-obestatin antibodyobestatin and anti-obestatin antibody insulin on
pAkt(S473) in 3T3-L1 pre-adipocytes. Phosphorylation was expressed as fold of control (n  3; meanS.E.). Blot is representative of three independent
experiments. Asterisk (*) denotes P  0.05 when comparing obestatin-treated group with anti-obestatin antibodyobestatin. (B) Effect of siRNA depletion
of preproghrelin on adipogenesis. 3T3-L1 cells transfected with preproghrelin siRNA prior to induction of adipocyte differentiation (DMEM/10% FBS with
insulin (172 nM) for 7 days after induction for 3 days under 0.5 mM IBMX, 25 M DEX and 861 nM insulin). Equal amounts of protein in each sample were
used to assess the expression of preproghrelin (left panel) by western blotting. Expression of preproghrelin was expressed as fold of the level of preproghre-
lin in control siRNA-transfected cells (meanS.E.). Lipid droplet accumulation was analysed by spectrophotometry at 520 nm by Oil red O staining (right
panel). Results are expressed as fold of lipid accumulation over differentiation control. Asterisk (*) denotes P 0.05 when comparing treated control siRNA
group with control siRNA group; dagger (#) denotes P  0.05 when comparing preproghrelin siRNA group with control siRNA group.
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Parallel to Akt activation, AMPK inactivation was triggered by
obestatin in 3T3-L1 pre-adipocyte and adipocyte cells. Similarly,
72 hrs continuous sc infusion of obestatin in vivo resulted in
decreased AMPK activity in WAT similar to that observed in vitro.
Thus, a decline in AMPK phosphorylation would be expected to
lead to a reduction in ACC phosphorylation, and thus an increase
in the activity of this enzyme. Accordingly, we found that ACC
phosphorylation was also decreased by obestatin in this study.
Based on it, increased ACC activity consequently leads to
increased malonyl Co-A levels, which mediate an inhibitory
effect on cholinephosphotransferase 1 (CPT-1), preventing fatty
acid transport into mitochondria and fatty acid oxidation, pro-
moting fatty acid synthesis [47]. Thus, Akt activation and AMPK
inactivation seem to be inversely correlated during obestatin
stimulation. This fact was confirmed in vivo in omental, subcu-
taneous and gonadal WAT obtained from male rats under contin-
uous sc infusion of obestatin. This enzymatic activity favours fat
deposition with the consequent inhibition of breakdown plus
burning stored fat and reduction of body weight. Furthermore,
obestatin works in a rapid, hormone-like manner, being its effect
insulin independent.
This study demonstrates a novel role for obestatin as an adi-
pogenic molecule. Based on the promoter role exerted by obestatin
on insulin-induced adipogenesis and the fact that obestatin expres-
sion increased in adipocytes compared to pre-adipocyte cells, we
postulated that obestatin might exert an autocrine/paracrine effect
on the differentiation process. The fact that preproghrelin expres-
sion increased in the course of differentiation process being sus-
tained throughout terminal differentiation of 3T3-L1 cells supports
our hypothesis. Furthermore, preproghrelin knockdown experi-
ments revealed its contribution to adipogenesis, although it would
involve both ghrelin and obestatin. The implication of obestatin
seems to be confirmed by neutralization of obestatin with specific
antibody in 3T3-L1 cells that reduced their adipogenic potential.
This is further supported by the effect of exogenous obestatin on
the expression of master regulators of adipocyte fate, C/EBP,
C/EBP, C/EBP and PPAR [48]. We can hypothesize that ghrelin
and obestatin mutually contribute to adipogenesis as pro-adipogenic
factors promoting lipogenesis. Indeed, it has been shown that
ghrelin stimulates lipid accumulation in vitro [13, 49] and 
in vivo [5, 10]. Thus, the original concept that these two peptides
derived from the same gene show opposite actions is not com-
pletely correct. Interestingly, ghrelin and obestatin knockdown by
preproghrelin siRNA revealed a key contribution of both peptides to
insulin-induced terminal adipogenesis suggesting that the insulin
effect might be mediated by expression and secretion of both pep-
tides on the late stage of adipogenesis.
The expression of GPR39 in 3T3-L1 cells and its expression
changes during adipogenesis suggests its implication in adipocyte
differentiation. This fits well with the expression pattern of GPR39
in mouse embryonic fibroblast cells during adipocyte differentia-
tion [25]. This hypothesis seems to be consistent with the up-reg-
ulation of preproghrelin expression and, in consequence, with the
increase of the biosynthesis and secretion of obestatin by
adipocytes, which exerts a paracrine control on pre-adipocyte via
a GPR39-dependent mechanism.
In summary, in this report we describe a novel role of obestatin in
the autocrine/paracrine regulation of adipogenesis. The adipogenic
role of obestatin is supported by: 1) the activation of Akt signaling, 2)
the regulation of adipocyte metabolism and, 3) the inhibition of adipo-
genesis by disruption of preproghrelin or netralization of obestatin.
Intriguingly, circulating obestatin and ghrelin levels do not increase in
obese subjects, a fact shared with ghrelin [50–52]. Therefore, neither
obestatin nor ghrelin appear to be determinant in maintaining obesity.
Nonetheless this fact does not rule out a function for obestatin in the
development of obesity. In this sense, it is remarkable that the magni-
fication of WAT is related to the development of the metabolic disor-
ders, and the identification of factors that participate to this phenome-
non would provide new aspects for the understanding of adipogenesis
as well as the pathogenesis of obesity and associated comorbidities.
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